There were no effective therapeutic options for advanced thyroid cancer until 5 years ago.
At the 2016 ASCO meeting, Vice President Joe Biden spoke about his vision for comprehensive data-sharing as part of the Cancer MoonShot initiative.
Mogamulizumab induced an encouraging response rate in patients with relapsed/refractory adult T-cell leukemia/lymphoma.
Cbimetinib and atezolizumab was well tolerated and demonstrated encouraging clinical activity in microsatellite stable colorectal cancer (CRC).
Funding, informatics system, clinical data capture, and European data protection legislation were considered the greatest barriers to effective data sharing.
Adding a second autologous hematopoietic cell transplantation (HCT) to standard therapy improves outcomes for pediatric patients with high-risk neuroblastoma.
MYL-1401O is comparable in efficacy and safety to the anti-HER2 monoclonal antibody trastuzumab as frontline therapy in breast cancer.
A Web application called Moovcare that guides follow-up improved survival for patients with advanced lung cancer after receiving initial therapy.
More transparency regarding the costs of various treatment regimens in real time is needed to "choose wisely" for patients, providers, and payers.
Physical exercise may have a direct effect on cancer that is as effective as drugs for treating patients with prostate cancer, even for those with advanced stages of the disease.
Disparities in cancer risk management among BRCA carriers across a diverse sample of young black, Hispanic, and non-Hispanic white breast cancer survivors underscores that "the benefit from genetic testing comes from acting on the test results," not just the testing itself, a study presented at the ASCO 2016 Annual Meeting concluded.
Multiplex gene testing of diverse patients has found that patients who test positive advise relatives to test, "suggesting that participants understood the implications of test results," according to results of a planned interim analysis of a prospective trial presented at the ASCO 2016 Annual Meeting.
"In the absence of patient-matched germline data, large germline databases are required in analysis workflows to minimize false positive mutation calling and mitigate ethnic disparities," a study presented at the ASCO 2016 Annual Meeting concluded.
Results showed that telephone disclosure was not worse than in-person disclosure for general and state anxiety.
"Patients who feel better, live longer." And, to help patients feel better, clinicians need to provide optimal symptom management, said Eric Roeland, MD, GI Oncology & Palliative Care, UC San Diego Moores Cancer Center, San Diego, California, discussant for 4 poster presentations at the ASCO 2016 Annual Meeting.
Final analysis of data from the phase 3 KEYNOTE-006 presented at the ASCO 2016 Annual Meeting confirm the superiority of pembrolizumab over ipilimumab for advanced melanoma.
At 3 years, 40% of patients with advanced melanoma treated with pembrolizumab are alive regardless of whether they had been treated with ipilimumab or not, follow-up results from the KEYNOTE-001 study reported at the ASCO 2016 Annual Meeting.
The longest overall survival follow-up among randomized phase 3 trials evaluating BRAF and MEK inhibitors in patients with BRAF-mutant metastatic melanoma to date has shown the best 3-year outcome with dabrafenib plus trametinib to be in patients with normal LDH and fewer than 3 disease sites, according to a presentation at the ASCO 2016 Annual Meeting.
Binimetinib may represent a new effective therapy for patients with NRAS-mutant melanoma, both before and after immunotherapy. That is the conclusion of the phase 3 NEMO study, results of which were presented at the ASCO 2016 Annual Meeting.
Adjuvant gemcitabine plus capecitabine significantly improved overall survival compared with gemcitabine monotherapy in patients with pancreatic ductal adenocarcinoma, according to results of the ESPAC-4 trial presented at the ASCO 2016 Annual Meeting.
NETTER-1 trial results of the somatostatin analogue peptide, 177Lu-DOTA0-Tyr3-octreotate (177Lu-Dotatate), suggest a potential survival benefit in patients with advanced midgut neuroendocrine tumors (NETs), attendees at the ASCO 2016 Annual Meeting were told.
In patients with advanced hepatocellular carcinoma (HCC), adding doxorubicin to sorafenib did not improve overall survival or progression-free survival and resulted in higher toxicity compared to sorafenib alone, results from a phase 3 study presented at the ASCO 2016 Annual Meeting have shown.
First results from the phase 3 CRITICS study found no significant difference in overall survival between postoperative chemotherapy and chemoradiotherapy in patients with resectable gastric cancer, according to a study presented at the ASCO 2016 Annual Meeting.
Daratumumab + Bortezomib/Dexamethasone: Reduced Risk of Disease Progression Seen in Relapsed or Refractory Multiple MyelomaJune 06, 2016
Adding daratumumab to bortezomib and dexamethasone was associated with a 61% reduction in risk of disease progression in patients with relapsed or refractory multiple myeloma (RRMM), according to results of the phase 3 CASTOR study presented in a plenary session at the ASCO 2016 Annual Meeting.
Adding Temozolomide to Radiotherapy Improves Survival in Elderly Patients With Newly Diagnosed GlioblastomaJune 06, 2016
The addition of temozolomide to standard short-course radiation therapy significantly improved both overall and progression-free survival in elderly patients with newly diagnosed glioblastoma, results from the first study to test this combination in this age group concluded in a plenary presentation at the ASCO 2016 Annual Meeting.
When added to the CHOP regimen, alemtuzumab increases remission rates in elderly patients with peripheral T cell lymphoma, final analysis of the international ACT-2 phase 3 trial presented at the ASCO 2016 Annual Meeting has shown.
Nimotuzumab + Radiotherapy Less Toxic Than Cisplatin + Radiotherapy for Stage III/IVB Nasopharyngeal CancerJune 05, 2016
Patients with locally advanced nasopharyngeal cancer concurrently treated with nimotuzumab and radiotherapy had similar rates of progression-free and overall survival to those treated with cisplatin and radiotherapy, but with significantly fewer GI and hematologic toxicities, according to phase 3 trial results presented at the ASCO 2016 Annual Meeting.
The role of antiangiogenic agents continues to evolve in the treatment of CNS cancers, attendees were told in a poster discussion session at the American Society of Clinical Oncology (ASCO) 2016 Annual Meeting.
The 2016 WHO Classification of Infiltrating Gliomas alters diagnostic criteria, providing the basis for clinical trial inclusion or exclusion based on an integrated diagnosis and setting the stage for all future research, according to a summary of 4 posters related to CNS biomarkers presented at the ASCO 2016 Annual Meeting.
Survival results from the first randomized phase 3 trial to compare cisplatin-radiotherapy with cetuximab-radiotherapy after induction chemotherapy in patients with locally advanced unresectable head and neck cancer remain inconclusive, with both arms showing good locoregional control, greater than 50% at 3 years, attendees at the ASCO 2016 Annual Meeting were told.
- Blood Test Predicts Stem Cell Transplant Success in Myelodysplastic Syndrome
- Immunotherapy and the Future of Prostate Cancer Treatment
- Trends in Behaviors, Medical Practice Indicate Mortality From Melanoma Will Decline
- Pembrolizumab Active Against Rare Melanoma, Extends Survival in Bladder Cancer
- Elderly with NSCLC Can Tolerate Aggressive Radiation Therapy Treatments
- Survivors Reporting Chronic Neuropathic Pain Struggle to Retain Jobs
- Lung Cancer Screening Rates Low Among Present and Former Smokers
- Timing of Chemotherapy Infusion Affects Inflammatory Response to Chemotherapy
- Postoperative Gemcitabine Plus Capecitabine: A New Standard of Care for Pancreatic Cancer
- Blood-Forming Stem Cell Transplants (Fact Sheet)
- Pediatric Hepatocellular Carcinoma: Challenges and Solutions
- Earlier and Later Adult BMI Associated With Multiple Myeloma Risk
- Cost-Effectiveness of Immunotherapy for Advanced Melanoma Evaluated
- VBPWPs Can Compliment Patient Management in Clinical Trials
- Communication Technology Improves Treatment Burden, Patient Perspective of Oncology Care
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|